SF3B1 Mutations Increase DCAF16 Expression to Create Targeted Therapeutic Vulnerability

Somatic mutations in the splicing factor SF3B1 are among the most frequent genetic alterations in chronic lymphocytic leukemia and myelodysplastic syndromes, where they serve as independent markers of poor clinical prognosis [1, 2, 3]. In a meta-analysis of 24,060 patients, these mutations were associated with a hazard ratio of 1.68 for overall survival [1]. These alterations disrupt alternative splicing, the regulatory process that allows a single gene to produce multiple protein isoforms, leading to the production of dysfunctional proteins that drive tumor proliferation and immune evasion [4, 5, 6]. While clinical management relies on genomic profiling to stratify risk, patients with these recurrent mutations often face relapsed or refractory disease; in such cases, multiple concurrent mutations are associated with a median progression-free survival of only 12 months [7, 8]. A new study now details how these splicing errors affect noncoding regions, which are DNA sequences that do not encode proteins but regulate their production, to create specific therapeutic vulnerabilities [9].